NCT01503359View on ClinicalTrials.gov

Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

January 31, 2016

Conditions
Schizophrenia
Interventions
DIETARY_SUPPLEMENT

Sarcosine

"Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months.~Placebo group patients will receive 2 grams of placebo once a day in the morning for 6 months."

Trial Locations (1)

92-216

Central Clinical Hospital, Lodz

All Listed Sponsors
lead

Medical University of Lodz

OTHER

NCT01503359 - Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia | Biotech Hunter | Biotech Hunter